Заключение

В заключение этой главы следует подчеркнуть, что понимание молекулярных механизмов патогенеза БА, и в частности метаболизма, предшественника амилоидного пептида, позволяет расширить сложившиеся на сегодняшний день представления о причинах возникновения этого нейродегенеративного заболевания, на развитие которого влияют многочисленные внешние и внутренние факторы и в патогенез которого вовлечены множественные метаболические процессы (рис.

Рис. 7. Схематическое изображение каскада патологических изменений, имеющих место при нейродегенерации и БА, и факторов, влияющих на их развитие

Литература

Дубровская Н.М., Наливаева Н.Н., Плеснева С.А. и др. Изменение активности амилоид-деградиру- ющих металлопептидаз приводит к нарушению памяти у крыс // ЖВНД. 2009. Т 59. № 5. С. 615-623.

Журавин И.А., Дубровская Н.М., Кочкина Е.Г. и др. Исследование действия гипоксии на развитие функций мозга и метаболизм амилоидного пептида с целью разработки средств ранней диагностики и профилактики болезни Альцгеймера // Технол. жив. сист. 2007. Т 4. № 5-6. С. 109-122.

Журавин И.А., Дубровская Н.М., ВасильевД.С. и др. Эпигенетическая и фармакологическая регуляция амилоид-деградирующего фермента неприлизина приводит к изменению когнитивных функций млекопитающих // Докл.

Козина Л.С., КочкинаЕ.Г., НаливаеваН.Н. и др. Влияние пептидов вилон и эпиталон на уровень экспрессии неприлизина и инсулин-деградирующего фермента в клетках нейробластомы человека в норме и при гипоксии //Нейрохимия. 2008. Т 25. № 1-2. С. 82-85.

Наливаева Н.Н., Бабусикова Е., Доброта Д., Тернер Э. Влияние ишемии и реперфузии на содержание предшественника амилоидного пептида и продуктов его протеолиза в гиппокампе крыс // Нейрохимия. 2005. Т 20. С. 1-6.

Наливаева Н.Н., Макова Н.З., Кочкина Е.Г. и др. Влияние геропротекторных пептидов на активность холинэстераз и образование растворимой формы предшественника амилоидного пептида в клетках нейробластомы человека SH-SY5Y // Нейрохимия. 2011. T. 28. № 3. C. 200-207.

СамойловМ.О. Реакция нейронов на гипоксию. Л.: Наука, 1985. 190 с.

Степаничев М.Ю., Моисеева Ю.В., Гуляева Н.В. «Инъекционные» модели болезни Альцгеймера: окислительный стресс в механизме токсичности AF64A и Р-амилоидного пептида у грызунов // Нейрохимия. 2002. Т 19. С. 165-175.

AllardS., Leon W.C., PakavathkumarP. etal. Impact of the NGF maturation and degradation pathway on the cortical cholinergic system phenotype // J. Neurosci. 2012. Vol. 32. № 6. P. 2002-2012.

Alikhani N., Guo L., Yan S. et al Decreased Proteolytic Activity ofthe MtochondrialAmyloid-P Degrading Enzyme, PreP Peptidasome, UiAlzheimei^jS Disease Brain Mitochondria // J. Alzheimers Dis. 2011. Vol. 27. № 1. P. 75-87.

Allinson T.M., Parkin E.T., Condon T.P. et al. The role ofADAM10 and ADAM 17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein // Eur. J. Biochem. 2004. Vol. 27. P. 539-547.

Alonso A., Zaidi T., NovakM. et al. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments // Proc. Natl. Acad. Sci. USA. 2001. Vol. 98. P. 6923-6928.

Apelt J., Schliebs R., BeckM. et al. Expression of amyloid precursor protein mRNA isoforms in rat brain is differentially regulated during postnatal maturation and by cholinergic activity // Int.

Apelt J., Ach K., Schliebs R. Ageing-related down-regulation of neprilysin, a putative b-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of b-amyloid plaques // Neurosci. Lett. 2003. Vol. 339. P. 183-186.

Arbel-Ornath M., Hudry E., Eikermann-Haerter K. et al. Interstitial fluid drainage is impaired in ischemic stroke and Alzheimer’s disease mouse models // Acta Neuropathol. 2013. Vol. 126. № 3. P. 353-364.

Asai M., Yagishita S., Iwata N. et al. An alternative metabolic pathway of amyloid precursor protein C- terminal fragments via cathepsin B in a human neuroglioma model // FASEB J. 2011. Vol. 25. № 10. P. 3720-3730.

Avila J., Lucas J. J., PerezM., Hernandez F. Role of tau protein in both physiological and pathological conditions // Physiol. Rev. 2004. Vol. 84. P. 361-384.

Aydin D., Weyer S.W., Muller U.C. Functions of the APP gene family in the nervous system: insights from mouse models // Exp. Brain Res. 2012. Vol. 217. P. 423-434.

Backstrom J.R., Lim G.P., Cullen M.J., Tokes Z.A. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-b peptide (1-40) // J. Neurosci. 1996. Vol. 16. P. 7910-7919.

Bai B., Hales C.M., Chen P.C. et al. U1 small nuclear ribonucleoprotein complex and RNA splicing altera-

tions in Alzheimer’s disease // Proc. Natl. Acad. Sci. USA. 2013. Vol. 110. № 41. P. 16562-16567.

Baig S., Kehoe P.G., Love S. MMP-2, -3 and -9 levels and activity are not related to Ap load in the frontal cortex in Alzheimer's disease // Neuropathol. Appl. Neurobiol. 2008. Vol. 34. P. 205-215.

Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders // Nat. Rev. Neurosci. 2007. Vol. 8. № 9. P. 663-672.

Barker R., Love S., Kehoe P.G. Plasminogen and plasmin in Alzheimer’s disease // Brain Res.

Barnes K., Walkden B.J., Wilkinson T.C., Turner A.J. Expression of endothelin-converting enzyme in both neuroblastoma and glial cell lines and its localization in rat hippocampus // J. Neurochem. 1997. Vol. 68. P. 570-577.

Barone E., Di Domenico F., Butterfield D.A. Statins more than cholesterol lowering agents in Alzheimer Disease: their pleiotropic functions as potential therapeutic TARGETS // Biochem. Pharmacol. 2013. pii: S0006-2952(13)00714-4. doi: 10.1016/j.bcp.2013.10.030.

Beckett C., Nalivaeva N.N., Belyaev N.D., Turner A.J. Nuclear signalling by membrane protein intracellular domains: the AICD enigma // Cell. Signal. 2012. Vol. 24. № 2. P. 402-409.

Bellingham S.A., Lahiri D. K., Maloney B. et al. Copper depletion down-regulates expression of Alzheimer’s disease Amyloid-P precursor protein gene // J. Biol. Chem. 2004. Vol. 279. P. 20378-20386.

Belyaev N.D., Nalivaeva N.N., Makova N.Z., Turner A.J. Neprilysin gene expression requires binding of the APP-intracellular domain to its promoter and is de-repressed by histone deacetylase inhibitors: implications for Alzheimer’s disease // EMBO J. 2009. Vol. 10. P. 94-100.

Belyaev N.D., Kellett K.A., Beckett C. et al. The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a Psecretase-dependent pathway // J. Biol. Chem. 2010. Vol. 285. № 53. P. 41443-41454.

Bennett I.J., Madden D.J. Disconnected Aging: Cerebral White Matter Integrity and Age-Related Differences in Cognition // Neuroscience. 2013. pii: S0306-4522(13)00973-1. doi: 10.1016/j.neuro- science.2013.11.026. [Epub ahead of print].

Bennett B.D., Babu-Khan S., Loeloff R. et al. Expression analysis of BACE2 in brain and peripheral tissues // J. Biol. Chem. 2000. Vol. 275. P. 20647-20651.

Bertram L., Tanzi R.E. Thirty years of Alzheimer’s disease genetics: the implications of systematic metaanalyses // Nat. Rev. Neurosci. 2008.

Bertram L., McQueen M.B., Mullin K. et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database // Nat. Genet. 2007. Vol. 39. P. 17-23.

BiglM., Apelt J., Eschrich K., Schliebs R Cortical glucose metabolism is altered in aged transgenic Tg2576 mice that demonstrate Alzheimer plaque pathology // J. Neural. Transm. 2003. Vol. 110. P. 77-94.

Blomqvist M.E., Silburn PA., Buchanan D.D. et al. Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease // Neurogenetics. 2004. Vol. 5. P. 115-119.

BodovitzS., FaldutoM.T., FrailD.E., Klein W.L. Iron levels modulate alpha-secretase cleavage of amyloid precursor protein // J. Neurochem. 1995. Vol. 64. № 1. P. 307-315.

Borchelt D.R., Thinakaran G., Eckman C.B. et al. Familial Alzheimer’s disease-linked presenilin 1 variants elevate AP1-42/1-40 ratio in vitro and in vivo // Neuron. 1996. Vol. 17. P. 1005-1013.

Brouillett J., Caillierez R., Zommer N. et al. Neurotoxicity and memory deficits induced by soluble low- molecular-weight amyloid-P1-42 oligomers are revealed in vivo by using a novel animal model // J. Neurosci. 2012. Vol. 32. P. 7852-7861.

Brouwers N., Sleegers K., Van Broeckhoven C. Molecular genetics of Alzheimer’s disease: an update // Ann. Med. 2008. Vol. 40. P. 562-583.

Bush A.I., Tanzi R.E. The galvanization of B-amyloid in Alzheimer’s disease // Proc. Natl. Acad. Sci. USA.

2002. Vol. 99. P. 7317-7319.

Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid b-peptide // Trends Mol. Med. 2002. Vol. 7. P. 548-554.

Buxbaum J.N., Ye Z., Reixach N. et al. Transthyretin protects Alzheimer’s mice from the behavioral and biochemical effects of Ap toxicity // Proc. Natl. Acad. Sci. USA. 2008. Vol. 105. P. 2681-2686.

Caccamo A., Oddo S., Sugarman M.C. et al. Age- and region-dependent alterations in AP-degrading enzymes: implications for AP-induced disorders // Neurobiol.

Cai J., QiX., KociokN. et al. P-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregu- lation and accumulation of age pigment // EMBO Mol. Med. 2012. Vol. 4. № 9. P. 980-991.

Caille I., AllinquantB., DupontE. et al. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone // Development. 2004. Vol. 131. P. 2173-2181.

Cairns N.J., Bigio E.H., Mackenzie I.R. et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration // Acta Neuropathol. 2007. Vol. 114. № 1. P 5-22.

Canet-Aviles R.M., Anderton M., Hooper N.M. et al. Muscarine enhances soluble amyloid precursor protein secretion in human neuroblastoma SH-SY5Y by a pathway dependent on protein kinase C(a), src-tyro- sine kinase and extracellular signal-regulated kinase but not phospholipase C // Brain Res. Mol. 2002. Vol. 102. P. 62-72.

Carty N., Nash K.R., Brownlow M. et al. Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice // PLoS One. 2013. Vol. 8. № 3. P e59626.

Caspersen C., Wang N., Yao J. et al. Mitochondrial Ap: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease // FASEB J. 2005. Vol. 19. P. 2040-2041.

Chasseigneaux S., Allinquant B. Functions of Ap, sAPPa and sAPPp : similarities and differences // J. Neu- rochem. 2012. Vol. 120. Suppl. 1. P 99-108.

Chen Z., Zhong C. Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies // Prog. Neurobiol. 2013. Vol. 108. P 21-43.

Chua L.M., Lim M.L., Wong B.S. The Kunitz-protease inhibitor domain in amyloid precursor protein reduces cellular mitochondrial enzymes expression and function // Biochem. Biophys. Res. Commun. 2013. Vol. 437. № 4. P. 642-647.

Citron B.A., Dennis J.S., Zeitlin R.S., Echeverria V. Transcription factor Sp1 dysregulation in Alzheimer’s disease // J. Neurosci. Res. 2008. Vol. 86. P. 2499-2504.

Corder E.H., Saunders A.M., Risch N.J. et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease // Nat. Genet. 1994. Vol. 7. P 180-184.

Cordy J.M., Hussain I., Dingwall C. et al. Exclusively targeting b-secretase to lipid rafts by GPI-anchor addition up-regulates P-site processing of the amyloid precursor protein // Proc. Natl. Acad. Sci. USA.

2003. Vol. 100. P 11735-11740.

Costa R., Ferreira-da-Silva F., Saraiva M.J., Cardoso I. Transthyretin protects against A-P peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor // PLoS One. 2008. Vol. 3. № 8. P e2899.

Coulson E.J., Paliga K., Beyreuther K., Masters C.L. What the evolution of the amyloid protein precursor supergene family tells us about its function // Neurochem. Int. 2000. Vol. 36. 175-184.

Crawford F.C., Freeman M.J., Schinka J.A. et al. A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer’s disease // Neurology. 2000. Vol. 55. P 763-768.

Cummings J.L., Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer’s disease // Am. J. Geriatr. Psychiatry. 1998. Vol. 6. Suppl. 1. P. 64-78.

De Strooper B. Aph-1, Pen-2 and Nicastrin with Presenilin generate an active g-Secretase complex // Neuron. 2003. Vol. 38. P 9-12.

Deng Y., Wang Z., Wang R. et al. Amyloid-P protein (AP) Glu11 is the major P-secretase site of P-site amyloid-P precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Ap Asp1 contributes to Alzheimer pathogenesis // Eur. J. Neurosci. 2013. Vol. 37. № 12. P 1962-1969.

Deuss M., Reiss K., Hartmann D. Part-time a-secretases: the functional biology of ADAM 9, 10 and 17 // Curr. Alzheimer Res. 2008. Vol. 5. P 187-201.

Di Legge S., Hachinski V. Prospects for prevention and treatment of vascular cognitive impairment // Curr. Opin. Invest. Drugs. 2003. Vol. 4. P. 1082-1087.

Dore S., KarS., Rowe W., Quirion R. Distribution and levels of [¹²⁵I]IGF-I, [¹²⁵I]IGF-II and [¹²⁵I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats // Neuroscience. 1997. Vol. 80. P 1033-1040.

Du J., ChoP.Y., YangD.T., Murphy R.M. Identification of P-amyloid-binding sites on transthyretin // Protein Eng. Des. Sel. 2012. Vol. 25. P 337-345.

Dubrovskaya N.M., Nalivaeva N.N., Vasilev D.S. et al. Mechanisms of short-term working memory deficit // Short-Term Memory: New Research. Eds. Garifallia Kalivas, Sappho F. Petralia. NY: Nova Science Publishers, Inc., 2012. Ch. 6. P 155-173.

Duckworth W.C., BennettR.G., HamelF.G. Insulin degradation: progress and potential // Endocr Rev. 1998. Vol. 19. P. 608-624.

Eckman E.A., Watson M., Marlow L. et al. Alzheimer’s disease b-amyloid peptide is increased in mice deficient in endothelin-converting enzyme // J. Biol. Chem. 2003. Vol. 278. P. 2081-2084.

Edbauer D., Willem M., Lammich S. et al. Insulin-degrading enzyme rapidly removes the P-amyloid precursor protein intracellular domain (AICD) // J. Biol. Chem. 2002. Vol. 277. P. 13389-13393.

Eggert S., Paliga K., Soba P. et al. The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation // J. Biol. Chem. 2004. Vol. 279. № 18. P. 18146-18156..

Ehehalt R., Keller P., Haass C. et al. Amyloidogenic processing of the Alzheimer b-amyloid precursor protein depends on lipid rafts // J. Cell Biol. 2003. Vol. 160. P. 113-123.

El-Agnaf O.M., Mahil D.S., PatelB.P., Austen B.M. Oligomerization and toxicity of b-amyloid-42 implicated in Alzheimer's disease // Biochem. Biophys. Res. Commun. 2000. Vol. 273. P. 1003-1007.

ElAliA., RivestS. The role ofABCB1 and ABCA1 in P-amyloid clearance at the neurovascular unit in Alzheimer’s disease // Front. Physiol. 2013. Vol. 4. P. 45.

Emoto N., Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensi- tive mettaloprotease with acidic pH optimum // J. Biol. Chem. 1995. Vol. 270. P. 15262-15268.

Erdos E.G., SkidgelR.A. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones // FASEB J. 1989. Vol. 3. P. 145-151.

Ertekin-Taner N., Ronald J., Feuk L. et al. Elevated amyloid-P protein (Ap42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene // Hum. Mol. Genet. 2005. Vol. 14. P. 447-460.

Fabbro S., Seeds N.W. Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain // J. Neurochem. 2009. Vol. 109. № 2. P. 303-315.

Fabbro S., Schaller K., Seeds N.W. Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer’s disease transgenic mouse model // J. Neurochem. 2011. Vol. 118. № 5. P. 928-938.

Facchinetti P., Rose C., Schwartz J.C., Ouimet T. Ontogeny, regional and cellular distribution of the novel metalloprotease neprilysin 2 in the rat: a comparison with neprilysin and endothelin-converting enzyme-1 // Neuroscience. Vol. 118. P. 627-639.

FahrenholzF. a-Secretase as a therapeutic target // Curr. Alzheimer Res. 2007. Vol. 4. P. 412-417.

Falkevall A., Alikhani N., Bhushan S. et al. Degradation of the amyloid P-protein by the novel mitochondrial peptidasome, PreP // J. Biol. Chem. 2006. Vol. 281. P. 29096-29104.

Farris W., Mansourian S., Leissring M.A. et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid b-protein // Am. J. Pathol. 2004. Vol. 164. P. 1425-1434.

Farzan M., Schnitzler C. E., Vasilieva N. et al. BACE2, a P-secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-P precursor protein // Proc. Natl. Acad. Sci. USA. 2000. Vol. 97. P. 9712-9717.

Ferretti M.T., Partridge V., Leon W.C. et al. Transgenic mice as a model of pre-clinical Alzheimer’s disease // Curr. Alzheimer Res. 2011. Vol. 8. P. 4-23.

Fisk L., Nalivaeva N.N., Turner A.J. Regulation of endothelin-converting enzyme-1 expression in human neuroblastoma cells // Exp. Biol. Med. 2006. Vol. 231. P. 1048-1053.

Fisk L., Nalivaeva N.N., Boyle J.P. et al. Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurones and astrocytes // Neurochem. Res. 2007. Vol. 32. P. 1741-1748.

Fodero L.R., Mok S.S., Losic D. et al. a7-nicotinic acetylcholine receptors mediate an AP(1-42)-induced increase in the level of acetylcholinesterase in primary cortical neurones // J. Neurochem. 2004. Vol. 88. P. 1186-1193.

Fraser P.E., Nguyen J.T., Inouye H.et al. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues ofAlzheimer amyloid P-protein // Biochemistry. 1992. Vol. 31. P. 10716-10723.

Gasparini L., Xu H. Potential roles of insulin and IGF-1 in Alzheimer’s disease // Trends Neurosci. 2003. Vol. 26. P. 404-406.

Ge Y.-W., Lahiri D. K. Regulation of promoter activity of the APP gene by cytokines and growth factors: implications in Alzheimer’s disease // Ann. NY Acad. Sci. 2002. Vol. 973. P. 463-467.

Ghaddar G., Ruchon A.F., CarpentierM. et al. Molecular cloning and biochemical characterization of a new mouse testis soluble-zinc-metallopeptidase of the neprilysin family // Biochem. J. 2000. Vol. 347. № 2. P. 419-429.

Ghiso J., Shayo M., Calero M. et al. Systemic catabolism of Alzheimer’s Ap40 and Ap42 // J. Biol. Chem.

2004. Vol. 279. P. 45897-45908.

Goate A., Hardy J. Twenty years of Alzheimer’s disease-causing mutations // J. Neurochem. 2012. Vol. 120. Suppl. 1. P 3-8.

Golomb J., de Leon M.J., Kluger A. et al. Hippocampal atrophy in normal aging. An association with recent memory impairment // Arch. Neurol. 1993. Vol. 50. P. 967-973.

Gregory G.C., Halliday G.M. What is the dominant Ap species in human brain tissue? A review // Neurotox. Res. 2005. Vol. 7. P. 29-41.

Griffiths H.H., Whitehouse I.J., Baybutt H. et al. Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein // J. Biol. Chem. 2011. Vol. 286. № 38. P 33489-33500.

Gu J., Zheng, J.Q. Microtubules in dendritic spine development and plasticity // Open Neurosci. J. 2009. Vol. 3. P 128-133.

Gunyuzlu P.L., White W.H., Davis G.L. et al. A yeast genetic assay for caspase cleavage of the amyloid-P precursor protein // Mol. Biotechnol. 2000. Vol. 15. P. 29-37.

Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid P-peptide // Nat. Rev. Mol. Cell. Biol. 2007. Vol. 8. P 101-112.

Haass C., Schlossmacher M.G., Hung A.Y. et al. Amyloid P-peptide is produced by cultured cells during normal metabolism // Nature. 1992. Vol. 359. P 322-325.

Han X., Rozen S., Boyle S.H. et al. Metabolomics in early Alzheimer’s disease: identification of altered plasma sphingolipidome using shotgun lipidomics // PLoS One. 2011. Vol. 6. P e21643.

Hardy J.A., Higgins G.A. Alzheimer’s disease: the amyloid cascade hypothesis // Science. 1992. Vol. 256. P 184-185.

Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. An updated summary of the amyloid hypothesis // Science. 2002. Vol. 297. P 353-356.

Hawkes C.A., Gatherer M., Sharp M.M. et al. Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid-P from the mouse brain // Aging Cell. 2013. Vol. 12. № 2. P 224-236.

He N., Jin W.L., Lok K.H. et al. Amyloid-P1-42 oligomer accelerates enescence in adult hippocampal neural stem/progenitor cells via formylpeptide receptor 2 // Cell Death. Dis. 2013. Vol. 4. P e924. doi: 10.1038/ cddis.2013.437.

Heber S., Herms J., Gajic V. et al. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members // J. Neurosci. 2000. Vol. 20. P 7951-7963.

Hebert S.S., Horre K., Nicolai L. et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/p-secretase expression // Proc. Natl. Acad. Sci. USA. 2008. Vol. 105. № 17. P 6415-6420.

Helbecque N., Cottel D., HermantX., Amouyel P. Impact of the matrix metalloproteinase MMP-3 on dementia // Neurobiol. Aging. 2007. Vol. 28. P 1215-1220.

Heldin C.H., Ericsson J. Signal transduction. RIPping tyrosine kinase receptors apart // Science. 2001. Vol. 294. P 2111-2113.

Hemming M.L., Selkoe D.J. Amyloid P-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor // J. Biol. Chem. 2005. Vol. 280. P 37644-37650.

Hemming M.L., Selkoe D.J., Farris, W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid P-protein metabolism in mouse models of Alzheimer disease // Neurobiol. Dis. 2007. Vol. 26. P. 273-281.

Hicks D.A., Nalivaeva N.N., Turner A.J. Lipid rafts and Alzheimer’s disease: protein-lipid interactions and perturbation of signalling // Front. Physiol. 2012. Vol. 3. P 189. doi: 10.3389/fphys.2012.00189.

Hitomi J., Katayama T., Eguchi Y. et al. Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and AP-induced cell death // J. Cell Biol. 2004. Vol. 165. P 347-356.

Holsinger R.M., Goense N., Bohorquez J., Strappe P. Splice variants of the Alzheimer’s disease P-secretase, BACE1 // Neurogenetics. 2013. Vol. 14. № 1. P. 1-9.

Holtzman DM, Mandelkow E, Selkoe DJ. Alzheimer disease in 2020 // Cold Spring Harb. Perspect. Med. 2012. Vol. 2. № 11. P. a011585.

Hong L., Koelsch G., Lin X. et al. Structure of the protease domain of memapsin 2 (P-secretase) complexed with inhibitor // Science. 2000. Vol. 290. P. 150-153.

Hook V., Hook G., KindyM. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce P-amyloid related to Alzheimer's disease // Biol. Chem. 2010. Vol. 391. P. 861-872.

Hooper N.M., Turner A.J. A new take on prions: preventing Alzheimer’s disease // Trends Biochem. Sci. 2008. Vol. 33. P. 151-155.

Hooper N.M., TurnerA.J. The search for a-secretase and its potential as a therapeutic approach to Alzheimer s disease // Curr. Med. Chem. 2002. Vol. 9. P. 1107-1119.

HoosM.D., AhmedM., Smith S.O., Van Nostrand W.E. Myelin basic protein binds to and inhibits the fibrillar assembly of Ap42 in vitro // Biochemistry. 2009. Vol. 48. P. 4720-4727.

Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease // Eur. J. Pharmacol. 2004. Vol. 490. P. 115-125.

Hu J., Igarashi A., Kamata M., Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid P-peptide (AP); retards Ap aggregation, deposition, fibril formation; and inhibits cytotoxicity // J. Biol. Chem. 2001. Vol. 276. P. 47863-47868.

Huang J.Y., Bruno A.M., Patel C.A. et al. Human membrane metallo-endopeptidase-like protein degrades both P-amyloid 42 and P-amyloid 40 // Neuroscience. 2008. Vol. 155. № 1. P. 258-262.

Huang J.Y., Hafez D.M., James B.D. et al. Altered NEP2 expression and activity in mild cognitive impairment and Alzheimer’s disease // J. Alzheimers Dis. 2012. Vol. 28. № 2. P. 433-41.

Ittner L.M., Gotz J. Amyloid-P and tau--a toxic pas de deux in Alzheimer’s disease // Nat. Rev. Neurosci. 2011. Vol. 12. № 2. P. 65-72.

Iwata N., Takaki Y., Fukami S. et al. Region-specific reduction of A b-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging // J. Neurosci. Res. 2002. Vol. 70. P. 493-500.

Iwata N., Mizukami H., Shirotani K. et al. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-P peptide in mouse brain // J. Neurosci. 2004. Vol. 24. P. 991-998.

Jacobsen K.T., IverfeldtK. Amyloid precursor protein and its homologues: a family of proteolysis-dependent receptors// Cell. Mol. Life Sci. Vol. 66. P 2299-2318.

Johnstone E. M., Chaney M. O., Norris F. H. et al. Conservation of the sequence of the Alzheimer’s disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis // Brain Res. Mol. Brain Res. 1991. Vol. 10. P. 299-305.

Jonsson T., Atwal J.K., Steinberg S. et al. A mutation in APP protects against Alzheimer’s disease and age- related cognitive decline // Nature. 2012. Vol. 488. № 7409. P. 96-99.

Jung C. K., Herms J. Role of APP for dendritic spine formation and stability // Exp. Brain Res. 2012. Vol. 217. P. 463-470.

Jurisch-Yaksi N., SannerudR., Annaert W. A fast growing spectrum of biological functions of y-secretase in development and disease // Biochim. Biophys. Acta. 2013. Vol. 1828. № 12. P. 2815-2827.

Kaeser S.A., Herzig M.C., Coomaraswamy J. et al. Cystatin C modulates cerebral P-amyloidosis // Nat. Genet. 2007. Vol. 39. P. 1437-1439.

KametaniF. s-secretase: reduction of amyloid precursor protein epsilon-site cleavage in Alzheimer's disease // Curr. Alzheimer Res. 2008. Vol. 5. P. 165-171.

KandalepasP.C., VassarR. Identification and biology of P-secretase // J. Neurochem. 2012. Vol. 120. Suppl. 1. P. 55-61.

Kanemitsu H., Tomiyama T., Mori H. Human neprilysin is capable of degrading amyloid b peptide not only in the monomeric form but also the pathological oligomeric form // Neurosci. Lett. 2003. Vol. 350. P. 113-116.

Katzov H., Bennet A.M., Kehoe P. et al. A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity // Hum. Mol. Genet. 2004. Vol. 13. P. 2647-2657.

Kauwe B., Van den Steen P.E., Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases // Crit. Rev. Biochem. 2007. Mol. Biol. Vol. 42. P. 113-185.

Kehoe P.G., Wilcock G.K. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? // Lancet Neurol. 2007. Vol. 6. P. 373-378.

Kehoe P.G., Katzov H., Feuk L. et al. Haplotypes extending across ACE are associated with Alzheimer’s disease // Hum. Mol. Gen. 2003. Vol. 12. P. 859-867.

Kern A., Roempp B., Prager K. et al. Down-regulation of endogenous amyloid precursor protein processing due to cellular aging // J. Biol. Chem. 2005. Vol. 281. P. 2405-2413.

Kerridge C., Belyaev N.D., Nalivaeva N.N. Turner A.J. The AP-clearance protein transthyretin (TTR), like neprilysin, is epigenetically regulated by the amyloid precursor protein intracellular domain (AICD) // J. Neurochem. 2014. Vol. 130. № 3. P. 419-431.

Kiko T., Nakagawa K., Tsuduki T. et al. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer’s disease // J. Alzheimers Dis. 2013. Vol. 39. № 2. P. 253-259.

Kim M.J., Chae S.S., Koh Y.H. et al. Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain // FASEB J. 2010. Vol. 24. P. 4491-4502.

Kimberly W.T., Xia W., Rahmati T. The transmembrane aspartates in presenilin 1 and 2 are obligatory for Y-secretase activity and amyloid P-protein generation // J. Biol. Chem. 2000. Vol. 275. P 3173-3178.

Kingston I. B., Castro M.J.M., Anderson S.A. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid b-peptide analogues // Nature Med. 1995. Vol. 1. R 138-142.

Kohli B.M., Pflieger D., Mueller L.N. et al. Interactome of the amyloid precursor protein APP in brain reveals a protein network involved in synaptic vesicle turnover and a close association with Synaptotagmin-1 // J. Proteome Res. 2012. Vol. 11. P. 4075-4090.

Koike H., Tomioka S., Sorimachi H. et al. Membrane-anchored metalloprotease MDC9 has an a-secretase activity responsible for processing the amyloid precursor protein // Biochem. J. 1999. Vol. 343. P. 371-375.

Kopan R., Ilagan M. X. The canonical Notch signaling pathway: unfolding the activation mechanism // Cell. 2009. Vol. 137. P 216-233.

KoudinovA.R., Berezov T.T. Alzheimer’s amyloid-P (AP) is an essential synaptic protein, not neurotoxic junk // Acta Neurobiol. Exp. (Wars). 2004. Vol. 64. P 71-79.

Kowalska A. Amyloid precursor protein gene mutations responsible for early-onset autosomal dominant Alzheimer’s disease // Folia Neuropathol. 2003. Vol. 41. P. 35-40.

Kracun I., Rosner H., Drnovsek V et al. Human brain gangliosides in development, aging and disease // Int. J. Dev. Biol. 1991. Vol. 35. P 289-295.

Kroner Z. The relationship between Alzheimer’s disease and diabetes: Type 3 diabetes? // Altern. Med. Rev. 2009. Vol. 14. № 4. P 373-379.

Kurochkin I.V., Goto S. Alzheimer’s b-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme // FEBS Lett. 1994. Vol. 345. P 33-37.

Lagouge M., Larsson N.G. The role of mitochondrial DNA mutations and free radicals in disease and ageing // J. Intern. Med. 2013. Vol. 273. № 6. P 529-543.

Lahiri D.K., Nall C. Promoter activity of the gene encoding the P-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1 // Brain Res. Mol. Brain Res. 1995. Vol. 32. P. 233-240.

Lahiri D.K., Zawia N.H., Greig N.H. et al. Early-life events may trigger biochemical pathways for Alzheimer’s disease: the «LEARn» model // Biogerontology. 2008. Vol. 9. P 375-379.

Lathia J.D., Mattson M.P., Cheng A. Notch: from neural development to neurological disorders // J. Neurochem. 2008. Vol. 107. P 1471-1481.

Lau P., Bossers K., Janky R. et al. Alteration of the microRNA network during the progression of Alzheimer’s disease // EMBO Mol. Med. 2013. Vol. 5. № 10. P 1613-1634.

Lauderback C.M., Hackett J.M., Huang F.F. et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer’s disease brain: the role of AP1-42 // J. Neurochem. 2001. Vol. 78. P 413-416.

Lauren J., Gimbel D.A., Nygaard H.B. et al. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers // Nature. 2009. Vol. 457. P 1128-1132.

Leal M.C., Dorfman V.B., Gamba A.F. et al. Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology // J. Neuropathol. Exp. Neurol. 2006. Vol. 65. P. 976-987.

Ledesma M.D., Da Silva J.S., Crassaerts K. et al. Brain plasmin enhances APP a-cleavage and Ab degradation and is reduced in Alzheimer's disease brains // EMBO Rep. 2000. Vol. 1. P. 530-535.

Ledesma M.D., Da Silva J.S., Schevchenko A. et al. Proteomic characterisation of neuronal sphingolipid- cholesterol microdomains: role in plasminogen activation // Brain Res. 2003. Vol. 987. P. 107-116.

Lefranc-Jullien S., Sunyach C., CheclerF. APPs, the s-secretase-derived N-terminal product of the P-amyloid precursor protein, behaves as a type I protein and undergoes a-, P- and y-secretase cleavages // J. Neu- rochem. 2006. Vol. 97. P. 807-817.

Lehmann .D.J., Cortina-Borja M., Warden D.R. et al. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker ofAlzheimer’s disease // Am. J. Epidemiol. 2005. Vol. 162. P. 305-317.

Leissring M.A., Farris W., Chang A.Y. et al. Enhanced proteolysis of b-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death // Neuron. 2003. Vol. 40. P. 10871093.

Leissring M.A., Farris W., Wu X. et al. Alternative translation initiation generates a novel isoform of insulindegrading enzyme targeted to mitochondria // Biochem. J. 2004. Vol. 383. P. 439-446.

Lewis J., Dickson D.W., Lin W.L. et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP // Science. 2001. Vol. 293. № 5534. P. 1487-1491.

Li H., Wang B., Wang Z. et al. Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP // Proc. Natl. Acad. Sci. USA. 2010. Vol. 107. № 40. P. 17362-17367.

Liao M.C., AhmedM., Smith S.O., Van Nostrand W.E. Degradation of amyloid P protein by purified myelin basic protein // J. Biol. Chem. 2009. Vol. 284. P. 28917-28925.

Lichtenthaler S.F., Wang R., Grimm H. et al. Mechanism of the cleavage specificity of Alzheimer’s disease g-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein // Proc. Natl. Acad. Sci. USA. 1999. Vol. 96. P. 3053-3058.

Lichtenthaler S.F., Haass C. Amyloid at the cutting edge: activation of a-secretase prevents amyloidogenesis in an Alzheimer disease mouse model // J. Clin. Invest. 2004. Vol. 113. P. 1384-1387.

Lilius L., Forsell C., Axelman K. et al. No association between polymorphisms in the neprilysin promoter region and Swedish Alzheimer’s disease patients // Neurosci. Lett. 2003. Vol. 337. P. 111-113.

Liu R., McAllister C., Lyubchenko Y., Sierks M.R. Proteolytic antibody light chains alter b-amyloid aggregation and prevent cytotoxicity // Biochemistry. 2004. Vol. 43. P. 9999-10007.

Liu Y., Yoo M.J., Savonenko A. et al. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer’s disease // J. Neurosci. 2008. Vol. 28. P. 13805-13814.

Liu R.M., van Groen T., Katre A. et al. Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer’s disease // Neurobiol. Aging. 2011. Vol. 32. P. 1079-1089.

Long J.M., Lahiri D.K. MicroRNA-101 downregulates Alzheimer’s amyloid-P precursor protein levels in human cell cultures and is differentially expressed // Biochem. Biophys. Res. Commun. 2011. Vol. 404. P. 889-895.

Long J.M., Ray B., Lahiri D.K. MicroRNA-153 physiologically inhibits expression of amyloid-P precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients // J. Biol. Chem. 2012. Vol. 287. P. 31298-31310.

Luo Y., Bolon B., Kahn S. et al. Mice deficient in BACE1, the Alzheimer’s P-secretase, have normal phenotype and abolished P-amyloid generation // Nat. Neurosci. 2001. Vol. 4. P. 231-232.

Ma Q.H., Futagawa T., Yang W.L. et al. A TAG1-APP signalling pathway through Fe65 negatively modulates neurogenesis // Nat. Cell Biol. 2008. Vol. 10. P. 283-294.

Mahley R.W., Huang Y., Weisgraber K.H. Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer’s disease // Curr. Alzheimer Res. 2007. Vol. 4. P. 537-540.

Maloney B., Ge Y. W., Greig N., Lahiri D.K. Presence of a «CAGA box» in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: implications in Alzheimer’s disease // FASEB J. 2004. Vol. 18. P. 1288-1290.

Marr R.A., Rockenstein E., Mukherjee A. et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice // J. Neurosci. 2003. Vol. 23. P. 1992-1996.

MarrR.A., SpencerB.J. NEP-like endopeptidases and Alzheimer’s disease // Curr. Alzheimer Res. 2010. Vol. 7. № 3. P. 223-229.

Martin B., de Maturana R.L., Brenneman R. et al. Class II G protein-coupled receptors and their ligands in neuronal function and protection // Neuromolecular. Med. 2005. Vol. 7. P. 3-36.

Martorana A., Sancesario G.M., Esposito Z. et al. Plasmin system of Alzheimer’s disease patients: CSF analysis // J. Neural. Transm. 2012. Vol. 119. № 7. P. 763-769.

Mattson M.P. Cellular action of b-amyloid precoursor protein and its soluble and fibrillogenic derivatives // Physiol. Rev. 1999. Vol. 77. P. 1081-1132.

Mattson M. Pathways towards and away from Alzheimer’s disease // Nature. 2004. Vol. 430. P. 631-639.

Mattson M.P., Guo Q., Furukawa K., Pedersen W.A. Presenilins, the endoplasmic reticulum, and neuronal apoptosis in Alzheimer’s disease // J. Neurochem. 1998. Vol. 70. P. 1-14.

Mattson M.P., Keller J.N., Begley J.G. Evidence for synaptic apoptosis // Exp. Neurol. 1998. Vol. 153. P. 35-48.

Mattson M.P., Duan W., Pedersen W.A., Culmsee C. Neurodegenerative disorders and ischemic brain diseases // Apoptosis. 2001. Vol. 6. P. 69-81.

McGowan E., Pickford F., Kim J. et al. Ap42 is essential for parenchymal and vascular amyloid deposition in mice // Neuron. 2005. Vol. 47. P. 191-199.

McKee A.C., Kowall N.W., Schumacher J.S., BealM.F. The neurotoxicity of amyloid P protein in aged primates // Amyloid. 1998. Vol. 5. P. 1-9.

Medeiros R., Baglietto-Vargas D., LaFerla FM. The role of tau in Alzheimer’s disease and related disorders // CNS Neurosci. Ther. 2011. Vol. 17. № 5. P. 514-524.

Mehta P.D., Pirttila T., PatrickB.A. et al. Amyloid b protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer’s disease // Neurosci. Letters. 2001. Vol. 304. P. 102-106.

Melzig M.F., Janka M. Enhancement of neutral endopeptidase activity in SK-N-SH cells by green tea extract // Phytomedicine. 2003. Vol. 10. P. 494-498.

Merlo S., Sortino M.A. Estrogen activates matrix metalloproteinases-2 and -9 to increase P amyloid degradation // Mol. Cell. Neurosci. 2012. Vol. 49. № 4. P. 423-429.

Mi W., PawlikM., Sastre M. et al. Cystatin C inhibits amyloid-P deposition in Alzheimer's disease mouse models // Nat. Genet. 2007. Vol. 39. P. 1440-1442.

Miners J.S., Ashby E., Van Helmond Z. et al. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer’s disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy // Neuro- pathol. Appl. Neurobiol. 2008. Vol. 34. P. 181-193.

Miyashita A., Koike A., Jun G. et al. SORL1 is genetically associated with late-onset Alzheimer’s disease in Japanese, Koreans and Caucasians // PLoS One. 2013. Vol. 8. № 4. P. e58618.

Mohajeri M.H., WollmerM.A., Nitsch RM. AP₄₂-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo // J. Biol. Chem. 2002. Vol. 277. P. 35460-35465.

Moir R.D., Lynch T., Bush A.I. et al. Relative increase in Alzheimer’s disease of soluble forms of cerebral Ap amyloid protein precursor containing the Kunitz protease inhibitory domain // J. Biol. Chem. 1998. Vol. 273. P. 5013-5019.

Montine T.J., Neely M.D., Quinn J.F. et al. Lipid peroxidation in aging brain and Alzheimer’s disease // Free Radic. Biol. Med. 2002. Vol. 33. P. 620-626.

Morelli L., Llovera R.E., Alonso L.G. et al. Insulin-degrading enzyme degrades amyloid peptides associated with British and Danish familial dementia // Biochem. Biophys. Res. Commun. 2005. Vol. 332. P. 808816.

MoriH., Takio K., OgawaraM., Selkoe D.J. Mass spectrometry of purified amyloid P protein in Alzheimer's disease // J. Biol. Chem. 1992. Vol. 267. P. 17082-17086.

Mrak R.E., Griffin W.S. Glia and their cytokines in progression of neurodegeneration // Neurobiol. Aging.

2005. Vol. 26. P. 349-354.

Mu Y., Gage F.H. Adult hippocampal neurogenesis and its role in Alzheimer’s disease // Mol. Neurodegen.

2011. Vol. 6. P. 85. doi: 10.1186/1750-1326-6-85.

Muller T., Meyer H.E., Egensperger R., Marcus K. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-Relevance for Alzheimer’s disease // Prog. Neurobiol. 2008. Vol. 85. P. 393-406.

Mueller-Steiner S., Zhou Y., Arai H. et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer’s disease // Neuron. 2006. Vol. 51. P. 703-714.

Nakagami Y., Abe K., Nishiyama N., Matsuki N. Laminin degradation by plasmin regulates long-term potentiation // J. Neurosci. 2000. Vol. 20. P2003-2010.

Nalivaeva N.N., Turner A.J. The amyloid precursor protein: a biochemical enigma in brain development, function and disease // FEBS Lett. 2013. Vol. 587. № 13. P. 2046-2054.

Nalivaeva N.N., Fisk L., Canet Aviles R.M. et al. Effect of prenatal hypoxia on expression of amyloid precursor protein and metallopeptidases in the rat brain // Lett. Peptide Sci. 2003. Vol. 10. P. 455-462.

Nalivaeva N.N., Fisk L., Kochkina E.G. et al. Effect of hypoxia/ischemia and hypoxic preconditioning/re- perfusion on expression of some amyloid-degrading enzymes // Ann. NY. Acad. Sci. 2004. Vol. 1035. P. 21-33.

Nalivaeva N.N., Fisk L.R., Belyaev N.D., Turner A.J. Amyloid-degrading enzymes as therapeutic targets in Alzheimer’s disease // Curr. Alzheimer Res. 2008. Vol. 5. P.212-224.

Nalivaeva N.N., Beckett C., Belyaev N.D., Turner A.J. Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease? // J. Neurochem. 2012а. Vol. 120. Suppl. 1. P. 167-185.

Nalivaeva N.N., Belyaev N.D., Lewis D.I. et al. Effect of sodium valproate administration on brain neprilysin expression and memory in rats // J. Mol. Neurosci. 2012b. Vol. 46. № 3. P. 569-377.

Nalivaeva N.N., Belyaev N.D., Zhuravin I.A., Turner A.J. The Alzheimer’s amyloid-degrading peptidase, neprilysin: can we control it? // Int. J. Alzheimers Dis. 2012c. Vol. 2012. P. ID 383796.

Namba Y., Tomonaga M., Kawasaki H. et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease // Brain Res. 1991. Vol. 541. P. 163-166.

NawrotB. Targeting BACE with small inhibitory nucleic acids - a future for Alzheimer’s disease therapy? // Acta Biochim. Pol. 2004. Vol. 51. P. 431-444.

Neale J.H., Olszewski R.T., Zuo D. et al. Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family // J. Neurochem. 2011. Vol. 118. P. 490-498.

Ni R., Marutle A., Nordberg A. Modulation of a7 nicotinic acetylcholine receptor and fibrillar amyloid-P interactions in Alzheimer’s disease brain // J. Alzheimers Dis. 2013. Vol. 33. № 3. P. 841-851.

Nicolls M.R. The clinical and biological relationship between Type II diabetes mellitus and Alzheimer’s disease // Curr. Alzheimer Res. 2004. Vol. 1. P. 47-54.

Nizzari M., Thellung S., Corsaro A. et al. Neurodegeneration in Alzheimer disease: role of amyloid precursor protein and presenilin 1 intracellular signalling // J. Toxicol. 2012. Vol. 2012. P. 187297. doi: 10.1155/2012/187297.

Octave J.N., Pierrot N., Ferao Santos S. et al. From synaptic spines to nuclear signaling: nuclear and synaptic actions of the amyloid precursor protein // J. Neurochem. 2013. Vol. 126. № 2. P. 183-190.

Ohrui T., Matsui T., Yamaya M. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer’s disease in Japan // J. Am. Geriatr. Soc. 2004. Vol. 52. P. 649-650.

Okamoto T., Takeda S., Murayama Y. et al. Ligand-dependent G protein coupling function of amyloid transmembrane precursor // J. Biol. Chem. 1995. Vol. 270. P. 4205-4208.

Okochi M., Tagami S., Yanagida K. et al. y-secretase modulators and presenilin 1 mutants act differently on presenilin/y-secretase function to cleave Ap42 and Ap43 // Cell. Rep. 2013. Vol. 3. № 1. P. 42-51.

Pacheco-Quinto J., Eckman E.A. Endothelin-converting enzymes degrade intracellular P-amyloid produced within the endosomal/lysosomal pathway and autophagosomes // J. Biol. Chem. 2013. Vol. 288. № 8. P. 5606-5615.

Palmer A.M., DeKosky S.T. Monoamine neurons in aging and Alzheimer’s disease // J. Neural. Transm. Gen. Sect. 1993. Vol. 91. P. 135-159.

Pandey S.C., Ugale R., Zhang H. et al. Brain chromatin remodeling: a novel mechanism of alcoholism // J. Neurosci. 2008. Vol. 28. P. 3729-3737.

Pardossi-Piquard R., Checler F. The physiology of the P-amyloid precursor protein intracellular domain AICD // J. Neurochem. 2012. Vol. 120. Suppl. 1. P 109-124.

Pardossi-Piquard R., Petit A., Kawarai T. et al. Presenilin-dependent transcriptional control of the AP- degrading enzyme neprilysin by intracellular domains of PAPP and APLP // Neuron. 2005. Vol. 46.

P. 541-554.

Park M.H., Lee J.K., Choi S. et al. Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer’s disease mice // Brain Res. 2013. Vol. 1529. P. 113-124.

Parkin E.T., Watt N.T., Hussain I. et al. Cellular prion protein regulates P-secretase cleavage of the Alzheimer's amyloid precursor protein // Proc. Natl. Acad. Sci. USA. 2007. Vol. 104. P. 11062-11067.

Parvathy S., Hussain I., Karran E.H. et al. Cleavage of Alzheimer’s amyloid precursor protein by a-secretase occurs at the surface of neuronal cells // Biochemistry. 1999. Vol. 38. P. 9728-9734.

Pearson H.A., Peers C. Physiological roles for amyloid beta peptides // J. Physiol. 2006. Vol. 575. P. 5-10.

Pedersen W.A., McMillan P.J., Kulstad J.J. et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice // Exp. Neurol. 2006. Vol. 199. P. 265-273.

Perez A., Morelli L., Cresto J.C., Castano E.M. Degradation of soluble amyloid b-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains // Neurochem. Res. 2000. Vol. 2. P. 247-255.

Perry T.A., GreigN.H. A new Alzheimer’s disease interventive strategy: GLP-1 // Curr. Drug. Targets. 2004. Vol. 5. P. 565-571.

Pfefferkorn T., Wiessner C., Allegrini P.R. et al. Plasminogen activation in experimental permanent focal cerebral ischemia // Brain Res. 2000. Vol. 882. P. 19-25.

Pluta R., Jablonski M., Ulamek-Koziol M. et al. Sporadic Alzheimer’s disease begins as episodes of brain ischemia and ischemically dysregulated Alzheimer’s disease genes // Mol. Neurobiol. 2013. Vol. 48. № 3. P. 500-515.

Postina R., SchroederA., Dewachter I. et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model // J. Clin. Invest. 2004. Vol. 113. P. 1456-1464.

Prince J.A., Feuk L., Gu H.F. et al. Genetic variation in a haplotype block spanning IDE influences Alzheimer disease // Hum. Mutat. 2003. Vol. 22. P. 363-371.

Qing H., He G., Ly P. T. et al. Valproic acid inhibits Ap production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models // J. Exp. Med. 2008. Vol. 205. P. 2781-2789.

Qiu W.Q., Walsh D.M., Ye Z. et al. Insulin-degrading enzyme regulates extracellular levels of amyloid b- protein by degradation // J. Biol. Chem. 1998. Vol. 273. P. 32730-32738.

Racchi M., Govoni S. The pharmacology of amyloid precursor protein processing // Exp. Gerontol. 2003. Vol 38. P. 145-157.

Rangan S.K., Liu R., Brune D. et al. Degradation of b-amyloid by proteolytic antibody light chains // Biochemistry. 2003. Vol. 42. P 14328-14334.

Riemenschneider M., Konta L., Friedrich P. et al. A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer’s disease // Hum. Mol. Genet. 2006. Vol. 15. P. 24462456.

Robert S., Maillet M., Morel E. et al. Regulation of the amyloid precursor protein ectodomain shedding by the 5-HT4 receptor and Epac // FEBS Lett. 2005. Vol. 579. P. 1136-1142.

Rogaev E.I., Sherrington R., Rogaeva E.A. et al. Familial AD in kindreds with missense mutations in a gene on chromosome 1 related to the AD type 3 gene // Nature. 1995. Vol. 376. P. 775-778.

Roher A.E,. Kasunic T. C., Woods A.S. et al. Proteolysis of Ap peptide from Alzheimer disease brain by gela- tinase A // Biochem. Biophys. Res. Commun. 1994. Vol. 205. P. 1755-1761.

Roher A.E., Weiss N., Kokjohn T.A. et al. Increased Ab peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease // Biochemistry. 2002. Vol. 37. P. 1108011090.

Roher A.E., Debbins J.P., Malek-Ahmadi M. et al. Cerebral blood flow in Alzheimer’s disease // Vasc. Health Risk Manag. 2012. Vol. 8. P. 599-611.

Rushworth J.V., Griffiths H.H., Watt N.T., Hooper N.M. Prion protein-mediated toxicity of amyloid-P oligomers requires lipid rafts and the transmembrane LRP1 // J. Biol. Chem. 2013. Vol. 288. № 13. P. 8935-8951.

Rybnikova E., Gluschenko T., Galeeva A. et al. Differential expression of ADAM15 and ADAM17 metallo- proteases in the rat brain after severe hypobaric hypoxia and hypoxic preconditioning // Neurosci. Res.

2012. Vol. 72. № 4. P. 364-373.

Sacha P., Zamernk J., Barinka C. et al. Expression of glutamate carboxypeptidase II in human brain // Neuroscience. 2007. Vol. 144. P. 1361-1372.

Sagare A.P., Bell R.D., Zlokovic B.V Neurovascular dysfunction and faulty amyloid P-peptide clearance in Alzheimer disease // Cold Spring Harb. Perspect. Med. 2012. Vol. 2. № 10. P. a011452.

Sahin U., Weskamp G., Kelly K. et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands // J. Cell Biol. 2004. Vol. 164. P. 769-779.

Saito T., Iwata N., Tsubuki S. et al. Somatostatin regulates brain amyloid P peptide Ap42 through modulation of proteolytic degradation // Nat. Med. 2005. Vol. 11. P. 434-439.

Sakai A., Ujike H., Nakata K. et al. Association of the neprilysin gene with susceptibility to late-onset Alzheimer’s disease // Dement. Geriatr. Cogn. Disord. 2004a. Vol. 17. P. 164-169.

Sakai A., Ujike H., Nakata K. et al. No association between the insulin degrading enzyme gene and Alzheimer’s disease in a Japanese population // Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2004b. Vol. 125B. P. 87-91.

Salta E., De Strooper B. Non-coding RNAs with essential roles in neurodegenerative disorders // Lancet Neurol. 2012. Vol. 11. P. 189-200.

Savaskan E., Hock C., Olivieri G. et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia // Neurobiol. Aging. 2001. Vol. 22. P. 541-546.

Sayre L.M., Zelasko D.A., Harris P.L. et al. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer’s disease // J. Neurochem. 1997. Vol. 68. P. 2092-2097.

Selkoe D.J. Preventing Alzheimer’s disease // Science. 2012. Vol. 337. № 6101. P 1488-1492.

Schilling S., Zeitschel U., Hoffmann T. et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Ap and Alzheimer’s disease-like pathology // Nat. Med. 2008. Vol. 14. R 1106-1111.

Shankar G.M., Li S., Mehta T.H. et al. Amyloid-P protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory // Nat. Med. 2008. Vol .14. P. 837-842.

Shen J., Bronson R.T., Chen D.F. et al. Skeletal and CNS defects in Presenilin-1-deficient mice // Cell. 1997. Vol. 89. P. 629-639.

Sherrington R., Rogaev E.I., Liang Y. et al. Cloning of a gene bearing missense mutations in early-onset familial AD // Nature. 1995. Vol. 375. P. 754-760.

Shi H., Belbin O., Medway C. et al. Genetic variants influencing human aging from late-onset Alzheimer’s disease (LOAD) genome-wide association studies (GWAS) // Neurobiol. Aging. 2012. Vol. 33. № 8. P. 1849.e5-18.

Shibata N., Ohnuma T., Higashi S. et al. Genetic association between matrix metalloproteinase MMP-9 and MMP-3 polymorphisms and Japanese sporadic Alzheimer’s disease // Neurobiol. Aging. 2005. Vol. 26. P. 1011-1014.

Shirotani K., Edbauer D., Prokop S. et al. Identification of distinct g-secretase complexes with different APH-1 variants // J. Biol. Chem. 2004. Vol. 279. P. 41340-41345.

Simons M., de Strooper B., Multhaup G. et al. Amyloidogenic processing of the human amyloid precursor protein in primary cultures of rat hippocampal neurons // J. Neurosci. 1996. Vol. 16. № 3. P. 899-908.

Sousa J.C., Cardoso I., Marques F. et al. Transthyretin and Alzheimer’s disease: where in the brain? // Neurobiol. Aging. 2007. Vol. 28. № 5. P. 713-718.

Stargardt A., Gillis J., Kamphuis W. et al. Reduced amyloid-P degradation in early Alzheimer’s disease but not in the APPswePS1dE9 and 3xTg-AD mouse models // Aging Cell. 2013. Vol. 12. № 3. P. 499-507.

Sun B., Zhou Y., Halabisky B. et al. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer’s disease // Neuron. 2008. Vol. 60. P 247-257.

Takahashi M., Fukuda K., Shimada K. et al. Localization of rat endothelin converting enzyme to vascular endothelial cells and some secretory cells // Biochem. J. 1995. Vol. 311. P. 657-665.

Tanaka S., Shiojiri S., Takahashi Y. et al. Tissue-specific expression of three types of P-protein precursor mRNA: enhancement of protease inhibitor-harboring types in Alzheimer’s disease brain // Biochem. Biophys. Res. Commun. 1989. Vol. 165. P 1406-1414.

Taru H., Yoshikawa K., Suzuki T. Suppression of the caspase cleavage of P-amyloid precursor protein by its cytoplasmic phosphorylation // FEBS Lett. 2004. Vol. 567. P. 248-252.

Thathiah A., Horre K., Snellinx A. et al. P-arrestin 2 regulates Ap generation and y-secretase activity in Alzheimer’s disease // Nat. Med. 2013. Vol. 19. № 1. P 43-49.

Thinakaran G., Kitt C.A., Roskams A.J. et al. Distribution of an APP homolog, APLP2, in the mouse olfactory system: a potential role for APLP2 in axogenesis // J. Neurosci. 1995. Vol. 15. P 6314-6326.

Toescu E.C., VerkhratskyA. Ca²+ and mitochondria as substrates for deficits in synaptic plasticity in normal brain ageing // J. Cell. Mol. Med. 2004. Vol. 8. P. 181-190.

Tsai K.J., Yang C.H., Lee P.C. et al. Asymmetric expression patterns of brain transthyretin in normal mice and a transgenic mouse model of Alzheimer’s disease // Neuroscience. 2009. Vol. 159. № 2. P. 638-646.

Tucker H.M., Kihiko-Ehmann M., Wright S. et al. Tissue plasminogen activator requires plasminogen to modulate amyloid-b neurotoxicity and deposition // J. Neurochem. 2000. Vol. 75. P. 2172-2177.

Tucker H.M., Kihiko-Ehmann M., Estus S. Urokinase-type plasminogen activator inhibits amyloid-b neurotoxicity and fibrillogenesis via plasminogen // J. Neurosci. Res. 2002. Vol. 70. P. 249-255.

Turner A.J., Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX // FASEB J. 1997. Vol. 11. P. 355-364.

Turner P.R., Bourne K., Garama D. et al. Production, purification and functional validation of human secreted amyloid precursor proteins for use as neuropharmacological reagents // J. Neurosci. Methods. 2007. Vol. 164. P. 68-74.

Tyan S.H., Shih A.Y., Walsh J.J. et al. Amyloid precursor protein (APP) regulates synaptic structure and function // Mol. Cell. Neurosci. 2012. Vol. 51. P. 43-52.

Usmani B.A., Harden B., Maitland N.J., Turner A.J. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines // Clin. Sci. (Lond). 2002. Vol. 103. Suppl. 48. P. 314-317.

Van den Hove D.L., Kompotis K., Lardenoije R. et al. Epigenetically regulated microRNAs in Alzheimer’s disease // Neurobiol. Aging. 2013. S0197-4580(13)00550-2 (in press).

Van Dijk R., Fischer D.F., Sluijs J.A. et al. Frame-shifted amyloid precursor protein found in Alzheimer’s disease and Down’s syndrome increases levels of secreted amyloid P40 // J. Neurochem. 2004. Vol. 90. P. 712-723.

Van Nostrand W.E., Porter M. Plasmin cleavage of the amyloid P-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity // Biochemistry. 1999. Vol. 38. P. 11570-11576.

VassarR. BACE1: the P-secretase enzyme in Alzheimer's disease // J. Mol. Neurosci. 2004. Vol. 23. P. 105114.

Venugopal C., Pappolla M.A., Sambamurti K. Insulysin cleaves the APP cytoplasmic fragment at multiple sites // Neurochem. Res. 2007. Vol. 32. № 12. P. 2225-2234.

Vincent B., Checler F. a-Secretase in Alzheimer’s disease and beyond: mechanistic, regulation and function in the shedding of membrane proteins // Curr. Alzheimer Res. 2012. Vol. 9. № 2. P. 140-156.

Walsh D.M., Klyubin I., Fadeeva J.V et al. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition // Biochem. Soc. Trans. 2002. Vol. 30. P. 552-557.

Walter J., van Echten-Deckert G. Cross-talk of membrane lipids and Alzheimer-related proteins // Mol. Neu- rodegener. 2013. Vol. 8. № 1. P. 34. [Epub ahead of print].

Wang D.S., Iwata N., Hama E. et al. Oxidized neprilysin in aging and Alzheimer’s disease brains // Biochem. Biophys. Res. Commun. 2003. Vol. 310. P. 236-241.

Wang S., WangR., Chen L. et al. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer’s brain // J. Neuro- chem. 2010. Vol. 115. № 1. P. 47-57.

Wang C., Sun B., Zhou Y. et al. Cathepsin B degrades amyloid-P in mice expressing wild-type human amyloid precursor protein // J. Biol. Chem. 2012. Vol. 287. № 47. P. 39834-39841.

Webster N.J., Green K.N., Settle VJ. et al. Altered processing of the amyloid precursor protein and decreased expression of ADAM 10 by chronic hypoxia in SH-SY5Y: no role for the stress-activated JNK and p38 signalling pathways // Brain Res. Mol. Brain Res. 2004. Vol. 130. P. 161-169.

Wehner S., Siemes C., Kirfel G., Herzog V. Cytoprotective function of sAPPalpha in human keratinocytes // Eur J. Cell Biol. 2004. Vol. 83. P. 701-708.

Weller R.O., Yow H.Y., Preston S.D. et al. Cerebrovascular disease is a major factor in the failure of elimination of Ab from the aging human brain // Ann. NY Acad. Sci. 2002. Vol. 977. P. 162-168.

Weyer S.W., Klevanski M., Delekate A. et al. APP and APLP2 are essential at PNS and CNS synapses for transmission, spatial learning and LTP // EMBO J. 2012. Vol. 30. P. 2266-2280.

White A.R., Reyes R., Mercer J.F. et al. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice // Brain Res. 1999. Vol. 842. P. 439-444.

White A.R., Du T., Laughton K.M. et al. Degradation of the Alzheimer disease amyloid P-peptide by metal- dependent up-regulation of metalloprotease activity // J. Biol. Chem. 2006. Vol. 281. P. 17670-17680.

Whyteside A.R., Turner A.J. Human neprilysin-2 (NEP2) and NEP display distinct subcellular localisations and substrate preferences // FEBS Lett. 2008. Vol. 582. P. 2382-2386.

Wiltfang J., Esselmann H., Cupers P. et al. Elevation of P-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells // J. Biol. Chem. 2001. Vol. 276. P. 4264542657.

Wolfe M.S. y-Secretase inhibitors and modulators for Alzheimer's disease // J. Neurochem. 2012. Vol. 120. Suppl. 1. P. 89-98.

Wolfe M.S. Toward the structure of presenilin/y-secretase and presenilin homologs // Biochim. Biophys. Acta.

2013. Vol. 1828. № 12. P 2886-2897.

Wu Z., Sun L., Hashioka S. et al. Differential pathways for interleukin-1p production activated by chrom- ogranin A and amyloid P in microglia // Neurobiol. Aging. 2013. Vol. 34. № 12. P. 2715-2725.

Xie L., Helmerhorst E., Taddei K. et al. Alzheimer’s b-amyloid peptides compete for insulin binding to the insulin receptor // J. Neurosci. 2002. Vol. 22. P RC221.

Xu D., Emoto N., Giaid A. et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1 // Cell. 1994. Vol. 78. P 473-485.

XuX., Zhou H., Boyer T.G. Mediator is a transducer of amyloid-precursor-protein-dependent nuclear signalling // EMBO Rep. 2011. Vol. 12. № 3. P 216-222.

Yan P., Hu X., Song H. et al. Matrix metalloproteinase-9 degrades amyloid-P fibrils in vitro and compact plaques in situ // J. Biol. Chem. 2006. Vol. 281. P 24566-24574.

Yasojima K., Akiyama H., McGeer E.G., McGeer P.L. Reduced neprilysin in high plaque areas of Alzheimer’s brain: a possible relationship to deficient degradation of b-amyloid peptide // Neurosci. Lett. 2001. Vol. 297. P 97-100.

Yildirim E., Zhang Z., Uz T. et al. Valproate administration to mice increases histone acetylation and 5-lipoxygenase content in the hippocampus // Neurosci. Lett. 2003. Vol. 345. P 141-143.

Yoshiyama Y., Asahina M., Hattori T. Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer’s disease brain // Acta Neuropathol. 2000. Vol. 99. P 91-95.

Young-Pearse T.L., Bai J., Chang R. et al. A critical function for P-amyloid precursor protein in neuronal migration revealed by in utero RNA interference // J. Neurosci. 2007. Vol. 27. P 14459-14469.

Zhang Z., Deng L., Yu H. et al. Association of angiotensin-converting enzyme functional gene I/D polymorphism with amnestic mild cognitive impairment // Neurosci. Lett. 2012. Vol. 514. № 1. P 131-135.

Zhao L.N., Long H., Mu Y., Chew L.Y. The Toxicity of Amyloid P Oligomers // Int. J. Mol. Sci. 2012. Vol. 13. № 6. P 7303-7327.

Zheng H., Jiang M., Trumbauer M.E. et al. P-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity // Cell. 1995. Vol. 81. P. 525-531.

Zhu G., Wang D., Lin Y.H. et al. Protein kinase C e suppresses Ab production and promotes activation of a-secretase // Biochem. Biophys. Res. Commun. 2001. Vol. 285. P 997-1006.

ZlokovicB.V. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease // JAMA Neurol. 2013. Vol. 70. № 4. P 440-444.

Zou K., Yamaguchi H., Akatsu H. et al. Angiotensin-converting enzyme converts amyloid P-protein 1-42 (A P₁₄₂) to AP₁₄₀, and its inhibition enhances brain A P deposition // J. Neurosci. 2007. Vol. 27. P 86288635. '

Zou K., Liu J., Watanabe A. et al. Ap43 is the earliest-depositing Ap species in APP transgenic mouse brain and is converted to Ap41 by two active domains of ACE // Am. J. Pathol. 2013. Vol. 182. № 6. P 23222331.